-0457 Pending Full Analysis of Clinical Data. 2007. at drugs/clinical trials/vertex-s-collaborator-merck-suspends-patient-enrollmentclinical-trials-mk-0457-vx-680-pending-full-2764.html 87. Chan WW, Wise SC, Kaufman MD, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by ETA-receptor the switch-control inhibitor DCC 2036. Cancer Cell. 2011, 19:556�?8. 88. Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006, 2:95�?02. 89. Deng X, Okram B, Ding Q, et al. Expanding the diversity of allosteric bcr-abl inhibitors. J Med Chem. 2010, 53:6934�?6. 90. Zhang J, Adrian FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-bindingsite inhibitors. Nature. 2010, 463:501�?.
91. Iacob RE, Zhang J, Gray NS, Engen Flt pathway JR. Allosteric interactions between the myristate- and ATPsite of the Abl kinase. PLoS One. 2011, 6:e15929. 92. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993, 13:7587�?5. 93. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002, 9:117�?0. 94. Beissert T, Puccetti E, Bianchini A, et al. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood. 2003, 102:2985�?3. 95. Dixon AS, Pendley SS, Bruno BJ, et al. Disruption of bcr-abl coiled coil oligomerization by design.
J Biol Chem. 2011, 286:27751�?0. 96. Zhang H, Trachootham D, Lu W, et al. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia. 2008, 22:1191�?. 97. Sun H, Kapuria V, Peterson LF, et al. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood. 2011, 117:3151�?2. Woessner et al. Page 14 Cancer J. Author manuscript, available in PMC 2012 May 1. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript 98. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Blood. 2002, 100:3041�?. 99. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003, 3:213�?. 100. Tsukahara F, Maru Y. Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood. 2010, 116:3582�?2. 101. Burchert A, Wolfl S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib , induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003, 101:259�?4. 102. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005, 365:657�?2. 103.
Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004, 103:1037�?2. 104. Telegeev GD, Dubrovska AN, Nadgorna VA, et al. Immunocytochemical study of Bcr and Bcr-Abl localization in K562 cells. Exp Oncol. 2010, 32:81�?. 105. van Denderen J, Hermans A, Meeuwsen T, et al. Antibody recognition of the tumor-specific bcrabl joining region in chronic myeloid leukemia. J Exp Med. 1989, 169:87�?8. 106. Perez-Martinez D, Tanaka T, Rabbitts TH. Intracellular antibodies